0.17%
14.02%
14.24%
20.23%
17.12%
12.60%
29.32%
AI Spotlight on BIM
Company Description
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors.It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories.
The company was formerly known as B-D Mérieux.bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France.bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Market Data
| Last Price | 117.1 |
| Change Percentage | 0.17% |
| Open | 116.8 |
| Previous Close | 116.9 |
| Market Cap ( Millions) | 13810 |
| Volume | 63939 |
| Year High | 117.6 |
| Year Low | 88.25 |
| M A 50 | 104.61 |
| M A 200 | 100.79 |
Financial Ratios
| FCF Yield | 1.13% |
| Dividend Yield | 0.73% |
| ROE | 10.80% |
| Debt / Equity | 14.44% |
| Net Debt / EBIDTA | 34.42% |
| Price To Book | 3.57 |
| Price Earnings Ratio | 33.58 |
| Price To FCF | 88.3 |
| Price To sales | 3.63 |
| EV / EBITDA | 16.95 |
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Clinical Applications
Expected Growth : 8.15 %
What the company do ?
Clinical Applications from bioMérieux S.A. provide diagnostic solutions for infectious disease diagnosis, antibiotic susceptibility testing, and molecular biology.
Why we expect these perspectives ?
Strong demand for microbiology and molecular diagnostics, increasing adoption of syndromic testing, and expansion in emerging markets drive bioMérieux's Clinical Applications segment growth. Additionally, the company's strategic acquisitions, innovative product launches, and partnerships with healthcare providers contribute to its 8.15% growth.
Segment n°2 -> Industrial Applications
Expected Growth : 8.1 %
What the company do ?
Industrial Applications from bioMérieux S.A. provide microbial detection and monitoring solutions for food, pharmaceutical, and cosmetics industries to ensure product quality and safety.
Why we expect these perspectives ?
Strong demand for industrial microbiology solutions, driven by increasing food safety regulations and growing need for quality control in pharmaceutical and cosmetic industries. bioMérieux's innovative product portfolio, including rapid testing solutions and automated systems, supports this growth. Additionally, strategic partnerships and acquisitions expand the company's presence in emerging markets, further fueling growth.
Biomérieux S.A. Products
| Product Range | What is it ? |
|---|---|
| FilmArray | A molecular diagnostics system that provides rapid and simultaneous detection of multiple pathogens from a single sample |
| VITEK 2 | An automated microbiology system that identifies and provides antibiotic susceptibility testing for bacteria and yeast |
| VIDAS | A range of immunoassay systems that provide rapid and accurate detection of infectious diseases, such as HIV, HBV, and HCV |
| API | A range of manual and automated systems for identifying and characterizing microorganisms |
| INDICAAT | A range of molecular diagnostic tests for infectious diseases, such as tuberculosis and influenza |
| NucliSENS easyMAG | A molecular diagnostics system that extracts and purifies nucleic acids from clinical samples |
bioMérieux S.A.'s Porter Forces
Threat Of Substitutes
bioMérieux S.A. operates in the in vitro diagnostics industry, which is characterized by a moderate threat of substitutes. While there are alternative diagnostic methods, they are not yet widely adopted, and bioMérieux's products remain a preferred choice for many healthcare professionals.
Bargaining Power Of Customers
bioMérieux S.A.'s customers, primarily healthcare providers and laboratories, have limited bargaining power due to the company's strong brand reputation and the complexity of its products.
Bargaining Power Of Suppliers
bioMérieux S.A. relies on a diverse supplier base, which reduces the bargaining power of individual suppliers. However, the company's dependence on a few critical suppliers for certain components may give them some negotiating power.
Threat Of New Entrants
The in vitro diagnostics industry has high barriers to entry, including significant R&D investments, regulatory hurdles, and the need for established distribution networks, making it challenging for new entrants to compete with bioMérieux S.A.
Intensity Of Rivalry
The in vitro diagnostics industry is highly competitive, with several established players, including Siemens Healthineers, Roche Diagnostics, and Abbott Diagnostics, competing fiercely for market share, which increases the intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 12.15% |
| Debt Cost | 3.95% |
| Equity Weight | 87.85% |
| Equity Cost | 4.69% |
| WACC | 4.60% |
| Leverage | 13.83% |
bioMérieux S.A. : Quality Control
bioMérieux S.A. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| QIA.DE | QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for … |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, … |
| ERF.PA | Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, … |
| SYAB.DE | SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers … |
| DIA.MI | DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Recordati
A-Score
1-Year Total Return ->
🥈
Synlab
A-Score
1-Year Total Return ->
🥉
DiaSorin
A-Score
1-Year Total Return ->
4
Qiagen
A-Score
1-Year Total Return ->
5
bioMérieux
A-Score
1-Year Total Return ->
6
